The sample copy of this report is available for access.
“Global Artificial Intelligence In Precision Medicine Market to reach a market value of USD 31,628.69 Million by 2033 growing at a CAGR of 37.8%”
The Global Artificial Intelligence In Precision Medicine Market is expected to reach USD 31628.7 million by 2033, growing at a CAGR of 37.8% during (2026 - 2033).
Rising demand for personalized treatment strategies, faster disease diagnosis, data-driven clinical decision-making, and efficient drug discovery is driving adoption of AI in precision medicine across healthcare providers, pharmaceutical companies, biotechnology firms, and research institutions. Growth is further strengthened by expanding genomics and multi-omics data, digital health adoption, biomarker discovery, AI-assisted diagnostics, patient stratification, therapy selection, and integrated clinical decision-support platforms. The market originated from the convergence of computational biology, genomics, and machine learning technologies. Early applications focused on basic analytics for genetic profiles, patient records, and clinical data interpretation.
Rising use of AI in precision medicine is driven by the healthcare industry’s shift from generalized treatment models toward individualized, data-driven care. AI enables clinicians and researchers to analyze complex biological and clinical datasets that are difficult to interpret through conventional methods. Growing use of genomic sequencing, digital pathology, wearable data, imaging analytics, and real-world evidence is strengthening the role of AI in diagnosis, prognosis, treatment planning, and patient monitoring. Pharmaceutical and biotechnology companies are also using AI to improve target discovery, trial design, biomarker validation, and personalized therapeutic development.
The competitive environment is moderately consolidated yet highly innovation-driven, with specialized AI healthcare companies, diagnostics firms, pharmaceutical-backed platforms, and computational biology players competing across precision oncology, genomics, real-world evidence, digital pathology, and AI-enabled drug discovery. Competition is shaped by the ability to access high-quality proprietary datasets, build clinically validated models, integrate with healthcare workflows, and comply with evolving medical AI regulations. Strategic partnerships between AI developers, hospitals, pharmaceutical companies, diagnostic labs, and research institutions are becoming essential for scaling AI-enabled precision medicine solutions.
The global Artificial Intelligence In Precision Medicine Market reflects a highly competitive and fragmented landscape, led by specialized precision oncology, genomic analytics, digital pathology, real-world evidence, and computational drug discovery companies. Tempus AI, Caris Life Sciences, Guardant Health, Roche, ConcertAI, SOPHiA GENETICS, PathAI, Owkin, Recursion Pharmaceuticals, and Personalis hold important positions through differentiated strengths in multimodal datasets, biomarker discovery, clinical validation, and AI-enabled therapeutic development. Market leadership is increasingly determined by proprietary healthcare data access, regulatory readiness, interoperability, explainability, and partnerships with hospitals, pharmaceutical companies, and research institutions.
Based on Component, the market is segmented into Software, Services, and Hardware. The Software market dominated the Global Artificial Intelligence In Precision Medicine Market by Component in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 12970.9 million by 2033, growing at a CAGR of 37.2 % during the forecast period. The Services market is expected to witness a CAGR of 38.3% during (2026 - 2033). The Hardware market is expected to witness a CAGR of 38.2% during (2026 - 2033).
Software forms the core layer of AI-enabled precision medicine as it includes algorithms, predictive analytics platforms, clinical decision-support tools, biomarker discovery solutions, and data interpretation systems. Services are essential for implementation, integration, consulting, workflow customization, regulatory support, and ongoing platform maintenance. Hardware supports the computational and diagnostic backbone of the market through high-performance computing, sequencing systems, imaging infrastructure, servers, and secure data-processing environments. Together, these components enable the collection, analysis, validation, and clinical use of complex patient-specific datasets.
Based on Technology, the market is segmented into Deep Learning, Natural Language Processing, Querying Method, and Context Aware Processing. The Deep Learning market dominated the Global Artificial Intelligence In Precision Medicine Market by Technology in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 10071.0 million by 2033, growing at a CAGR of 36.8 % during the forecast period. The Natural Language Processing market is expected to witness a CAGR of 38% during (2026 - 2033). Additionally, The Querying Method market is expected to witness highest CAGR of 38.5% during (2026 - 2033).
Deep Learning plays a major role in analyzing imaging, genomic, pathology, and multi-omics datasets where complex pattern recognition is required. Natural Language Processing supports extraction of insights from clinical notes, electronic health records, research literature, and unstructured medical documents. Querying Method enables efficient retrieval and interpretation of large biomedical databases, clinical repositories, and patient records. Context Aware Processing strengthens precision medicine by linking patient-specific clinical, molecular, demographic, and treatment-context information to generate more relevant care recommendations.
Based on Therapeutic Application, the market is segmented into Oncology, Cardiology, Neurology, Respiratory, and Other Therapeutic Application. The Oncology market dominated the Global Artificial Intelligence In Precision Medicine Market by Therapeutic Application in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 9347.7 million by 2033, growing at a CAGR of 36.7 % during the forecast period. The Cardiology market is expected to witness a CAGR of 37.5% during (2026 - 2033). Additionally, The Neurology market is expected to witness highest CAGR of 38.2% during (2026 - 2033).
Oncology remains a highly prominent application area due to the strong use of genomic profiling, tumor characterization, biomarker discovery, liquid biopsy, and companion diagnostics. Cardiology applications are expanding through risk prediction, disease progression monitoring, imaging analytics, and patient-specific treatment planning. Neurology benefits from AI-driven analysis of neuroimaging, cognitive data, genetic markers, and disease progression patterns. Respiratory applications are gaining relevance through early disease detection, pulmonary risk assessment, remote monitoring, and personalized care for chronic respiratory conditions, while other therapeutic areas include rare diseases, infectious diseases, immunology, metabolic disorders, and pharmacogenomics.
Free Valuable Insights: Artificial Intelligence In Precision Medicine Market Size to reach $31628.6 Million by 2033
Region-wise, the Artificial Intelligence In Precision Medicine Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America market dominated the Global Artificial Intelligence In Precision Medicine Market by Region in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 16469.1 million by 2033, growing at a CAGR of 37.3 % during the forecast period. The Europe market is expected to witness a CAGR of 37.5% during (2026 - 2033). Additionally, The Asia Pacific market is expected to witness a CAGR of 38.8% during (2026 - 2033).
North America remains a major regional market due to strong healthcare data infrastructure, advanced biopharma activity, high AI investment, and early adoption of precision oncology and clinical decision-support platforms. Europe benefits from healthcare digitization, multi-omics research, public funding, structured data-governance frameworks, and growing regulatory clarity around responsible AI adoption. Asia Pacific is expanding through rising genomic research, healthcare AI initiatives, digital health adoption, and increasing precision medicine investments in countries such as China, Japan, India, South Korea, Singapore, and Malaysia. LAMEA is developing steadily as healthcare modernization, AI diagnostics, remote monitoring, and localized precision medicine initiatives gain momentum.
| Report Attribute | Details |
|---|---|
| Market size value in 2026 | USD 3350.8 million |
| Market size forecast in 2033 | USD 31628.6 million |
| Base Year | 2025 |
| Historical Period | 2022 to 2024 |
| Forecast Period | 2026 to 2033 |
| Revenue Growth Rate | CAGR of 37.8% from 2026 to 2033 |
| Number of Pages | 573 |
| Tables | 690 |
| Report Coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Market Share Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Product Life Cycle Analysis, Value Chain Analysis, Market Consolidation Analysis, Key Customer Criteria, Pandemic Impact Analysis, and Winning Imperatives |
| Segments Covered | Component, Technology, Therapeutic Application, and Geography |
| Country Scope |
|
| Companies Included | Tempus AI; Caris Life Sciences; Guardant Health, Inc.; Roche; ConcertAI; SOPHiA GENETICS SA; PathAI, Inc.; Owkin, Inc.; Recursion Pharmaceuticals, Inc.; Personalis, Inc. |
By Component
By Technology
By Therapeutic Application
By Geography
Expected to reach USD 31,628.7 million by 2033, growing at 37.8% CAGR during 2026-2033.
AI-driven biomarker discovery is a key growth driver in precision medicine.
Tempus AI, Caris Life Sciences, Guardant Health, Inc., Roche, and ConcertAI lead the market.
AI-enabled drug discovery and enhanced clinical decision support are major growth drivers.
Details on regional dominance are not specified in the provided data.
The market grows at 37.8% CAGR during the forecast period (2026-2033).
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 